Аcute ulcer and erosion of the gastrointestinal tract induced by non-steroidal anti-inflammatory drugs: etiology, pathogenesis, treatment tactics

Abstract

This article reviews the latest developments in understanding the etiology, pathogenesis, risk factors, treatment and prevention of gastroand enteropathy caused by nonsteroidal anti-inflammatory drugs. Risk factors, modern therapeutic tactics of patients receiving non-steroidal anti-inflammatory drugs, as well as prevention of this disease have been considered. Nonsteroidal antiinflammatory drugs are widely used in the world due to their anti-inflammatory, analgesic and antipyretic activity. One of the major factors limiting the use of these drugs is their side effects on the gastrointestinal tract. Currently, the incidence of complications of the upper gastrointestinal tract reduces, and the rate of complications from the lower divisions increases. The clinical significance of enteropathy induced by nonsteroidal anti-inflammatory drugs remains undervalued, despite the danger and threat to the life of patients. Effects of the use of non-steroidal anti-inflammatory drugs in the intestine are poorly understood and are not always familiar to clinicians, and diagnosis of this disease is quite difficult. The pathogenesis of enteropathy is different from the pathogenesis of ulcer and erosion of the upper gastrointestinal tract, caused by nonsteroidal anti-inflammatory drugs. Treatment, and prevention are significantly different too. Demonstrated promising protection areas of the gastrointestinal tract by using and creating new products, in particular contain hydrogen sulphide, and nitrogen oxide. Particular attention is given to consideration of the data supporting the new ideas about how to glucocorticoid hormones important natural gastroprotective factors whose role becomes especially important in the conditions of oppression of prostaglandin production, occurring when taking non-steroidal anti-inflammatory drugs.

Keywords

non-steroidal anti-inflammatory drugs / ulcer / erosion / gastrointestinal tract / gastroprotection / glucocorticoids / gastropathy / enteropathy / prostaglandin / proton pump inhibitors

References

[1] Затевахин, И.И. Абдоминальная хирургия. Национальное руководство: краткое издание / Под ред. И.И. Затевахина, А.И. Кириенко, В.А. Кубышкина. – М.: ГЭОТАР-Медиа, 2016. – 912 с.

[2] Филаретова, Л.П. Гастропротективная роль глюкокортикоидных гормонов при действии нестероидных противовоспалительных веществ / Л.П. Филаретова [и др.] // Росс. физиол. журн. им. И.М. Сеченова. – 2009. – № 3 (95). – С. 250–261.

[3] Chan, F.K. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment / F.K. Chan, D.Y. Graham // Aliment Pharmacol Ther. – 2004. – Vol. 19. – P. 1051–1061.

[4] Dib, R.A. Ulcer and bleeding complications and their relationship with dyspeptic symptoms in NSAIDs users: a transversal multicenter study / R.A. Dib [et al.] // Scandinavian Journal Of Gastroenterology. – 2014. – Vol. 49 (7). – P. 785–789.

[5] Filaretova, L.P. Mechanisms by which endogenous glucocorticoids protects against indomethacin-induced gastric injury in rats / L.P. Filaretova [et al.] // Am. J. Physiol. – 2002. – № 5 (83). – Р. 1082–1089.

[6] Filaretova, L.P. The healing of NSAID-induced gastric lesion may be followed by small intestinal and cardiovascular side effects / L.P. Filaretova [et al.] // Physiol Pharmacol. cology. – 2011. – № 62 (6). – Р. 619–625.

[7] Filaretova, L.P. From gastroprotective to ulcerogenic effects of glucocorticoids: role of long-term glucocorticoid action / L.P. Filaretova [et al.] // Curr. Pharm. Des. – 2014. – Vol. 20 (7) – Р. 1045–1050.

[8] Filaretova, L.P. Aggravation of nonsteroidal antiinflammatory drug gastropathy by glucocorticoid deficiency or blockade of glucocorticoid receptor in rats / L.P. Filaretova [et al.] // Life Sci. – 2002. – Vol. 71 (21). – Р. 2457–2468.

[9] Goldstein, J.L. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo / J.L. Goldstein [et al.] // Clin. Gastroenterol. Hepatol. – 2005. – Vol. 3. – P. 133–141.

[10] Goldstein, J.L. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies / J.L. Goldstein [et al.] // Drug, Healthcare And Patient Safety. – 2015. – Vol. 7. – P. 31–41.

[11] Hawkey, C.J. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole / C.J. Hawkey [et al.] // Clin. Gastroenterol. Hepatol. – 2008. – Vol. 6. – P. 536–544.

[12] Kodela, R. NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals // R. Kodela, M. Chattopadhyay, K. Kashfi // ACS Med Chem Lett. – 2012. – № 3. – P. 257–262.

[13] Lanas, A. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? / A. Lanas, C. Scarpignato // Digestion. – 2006. – Vol. 73 (1). – P. 136–50.

[14] Lanza, F.L. Guidelines for prevention of NSAID-related ulcer complications / F.L. Lanza, F.K.L. Chan, E.M.M. Quigley // Am J Gastroenterol. – 2009. – Vol. 104. – P. 728–738.

[15] Lichtenberger, L.M. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity /

[16] L.M. Lichtenberger [et al.] // Drugs Today. – 2009. – № 45. – Р. 877–890.

[17] Momeni, M. Mitigating GI risks associated with the use of NSAIDs / M. Momeni, J.D. Katz // Pain Medicine. – 2013. – Vol. 14 (1). – P. 18–22.

[18] Montalto, M. Clinical trial: the effects of a probiotic mixture on non-steroidal antiinflammatory drug enteropathy – a randomized, doubleblind, cross-over, placebo-controlled study / M. Montalto [et al.] // Aliment Pharmacol Ther. – 2010. – Vol. 32. – P. 209–214.

[19] Park, J.M. Omega-3 polyunsaturated fatty acids as an angelus custos to rescue patients from NSAID-induced gastroduodenal damage / J.M. Park [et al.] // Journal Of Gastroenterology. – 2015. – Vol. 50 (6). – Р. 614–625.

[20] Reuter, B.K. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation / B.K. Reuter [et al.] // Gastroenterology. – 1997. – Vol. 112. – P. 109–117.

[21] Sakai, E. Factors predicting the presence of small bowel lesions in patients with obscure gastrointestinal bleeding / E. Sakai [et al.] // Dig Endosc. – 2012. – Vol. 25. – P. 412–420.

[22] Satoh, H. Management of NSAID/aspirin-induced small intestinal damage by GI-sparing NSAIDs, anti-ulcer drugs and food constituents / H. Satoh, K. Takeuchi // Current Medicinal Chemistry. – 2012. – Vol. 19 (1). – P. 82–89.

[23] Syer, S.D. NSAID enteropathy and bacteria: a complicated relationship //S.D. Syer [et al.]// Journal Of Gastroenterology. – 2015. – Vol. 50 (4). – P. 383–393.

[24] Wallace, J.L. Polypharmacy of Osteoarthritis: The Perfect Intestinal Storm / J.L. Wallace // Dig Dis Sci. – 2013. – Vol. 58. – P. 3088–3093.

[25] Wallace, J.L. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy / J.L. Wallace // World J Gastroenterol. – 2013. – Vol. 19 (12). – P. 1861–1876.

[26] Wallace, J.L. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis /J.L. Wallace [et al.] // Gastroenterology. – 2011. – Vol. 141. – P. 1314–1322.

[27] Wang, X. Meta-analysis: Cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis / X. Wang [et al.] // Eur. J. Gastroenterol. Hepatol. – 2011. – Vol. 23 (10). – P. 876–80.

[28] Watanabe, T. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study / T. Watanabe [et al.] // Clin. Gastroenterol. Hepatol. – 2008. – Vol. 6. – P. 1279–1282.

[29] Watanabe, T. Risk factors for severe nonsteroidal antiinflammatory drug-induced small intestinal damage / T. Watanabe [et al.] // Dig Liver Dis. – 2013. – Vol. 45. – P. 390–395.

Funding

Работа поддержана грантом Российского научного фонда(14-15-00790)

RIGHTS & PERMISSIONS

Eco-Vector